Outsourced Pharma White Papers

  1. Building Excellence In Pharma Manufacturing Through Rigor 8/16/2025

    A rigorous, proactive approach is essential for excellence in pharmaceutical manufacturing. Learn how embedding rigor in systems, workflows, and workforce capabilities improves compliance and efficiency.

  2. Safety, Containment, And Analysis Of Highly Potent Compounds 5/16/2024

    Explore a comprehensive overview of the challenges, requirements, and best practices for safely working with highly potent compounds in drug development and manufacturing.

  3. Solid State Hydrogen Deuterium Exchange To Study Antibody Drug Conjugate Stability 10/16/2024

    Discover how this solid-state HDX-MS is being used to revolutionize the prediction of stability for IgG-based antibody drug conjugates and enhance ADC development processes.

  4. Nose To Brain (N2B) Drug Delivery – Benefits And Challenges 11/20/2024

    Delve into the growing interest in drug delivery methods that target the brain and central nervous system via absorption into the bloodstream, specifically focusing on crossing the blood-brain barrier (BBB).

  5. Applications Of Liquid-Filled Capsules For Challenging APIs In Pharmaceutical Manufacturing 11/27/2024

    Discover the benefits of liquid-filled capsules for efficient, scalable, and patient-friendly drug manufacturing, and how they can enhance bioavailability and simplify complex formulations.

  6. Achieving Rapid, High-Titer Expression For Next-Generation Biologics 3/5/2025

    This advanced cell line development technology overcomes production challenges related to the expression and scalability of complex biologics.

  7. Sustainability In Small Molecule API Manufacturing 11/7/2025

    Redesigning chemical processes with green chemistry principles can cut emissions, reduce waste, and improve efficiency. See how smarter synthesis and digital tools enable sustainable API manufacturing.

  8. A CFO's Guide To Driving Growth 3/25/2025

    Navigate the evolving biotech landscape and secure venture capital with insights on strategic partnerships and investor expectations.

  9. Improvements In ADC Efficacy And Stability 3/17/2026

    Antibody-drug conjugates combine targeted antibodies with potent cytotoxic payloads, but increasing hydrophobicity challenges stability, manufacturability, and pharmacokinetics, driving interest in hydrophilic linker strategies to improve performance.

  10. Key Selection Criteria For Cell & Gene Therapy CDMOs 3/4/2026

    Choosing the right CDMO requires early internal assessment plus strong technical capability, agility, advocacy, clear communication, and long‑term alignment to meet evolving cell and gene therapy needs.